Background: Substance use, a leading cause of illness and death, is underidentified in medical practice.
Study Procedures
Study visits were completed in a private room. Participants were assigned a unique identifier and were told that responses were confidential and would not be shared with anyone in the clinic. The electronic data capture system randomly assigned half of the participants to begin with the self-administered TAPS tool and half to begin with the interviewer-administered version. After completing the TAPS tool in the first format (for example, self-administered), the participants completed it in the other version (for example, intervieweradministered). The self-administered version was delivered on a tablet computer (iPad, Apple), which gave participants the option of hearing the questions and response options read verbatim by a recorded female voice. For the interviewer version, the RAs read all the questions and response options aloud to the participants. After both versions were completed, the RA administered a questionnaire about the feasibility and acceptability of the TAPS tool; then, additional substance use measures were collected for comparison purposes. The RAs were not blinded to participant responses on the interviewer-administered TAPS tool when they administered the reference standard measure: the modified World Health Organization World Mental Health Composite International Diagnostic Interview (www .hcp.med.harvard.edu/wmhcidi/index.php) here referred to as CIDI. After completing self-reported assessments, all participants were asked to provide verbal consent to participate in oral fluid testing for drugs. Participants received $20 for the main study and an additional $10 for oral fluid testing. All study procedures were approved by local institutional review boards (Duke University Health System, Friends Research Institute, New York University School of Medicine, and Virginia Commonwealth University).
Measures

Experimental Instrument: TAPS Tool
The TAPS tool was developed as a 2-step screening and brief assessment approach from instruments that had not been validated. The screening component, TAPS-1, was adapted from NIDA Quick Screen V1.0 (31), whereas the brief assessment component, TAPS-2, is a modified version of the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST)-Lite (32) . A prototype of the TAPS tool was evaluated through cognitive interviews (33-35) with 30 adult primary care patients from 3 of the study sites. On the basis of these interviews, the wording of TAPS tool items was modified slightly before the instrument was finalized for use in this study.
The tool is shown in Figure 1 . The TAPS-1 component asked how frequently in the previous 12 months the participant used tobacco, alcohol (above guidelinerecommended daily limits: 5 or more drinks per day for men; 4 or more drinks per day for women [36] ), illicit drugs, or prescription medications (sedatives, opioids, and stimulants) for nonmedical purposes. Respondents chose from 5 options ranging from "never" to "daily or almost daily." In TAPS-2, participants answered "yes" or "no" to questions regarding use of tobacco, alcohol, 6 classes of illicit drugs, and "other" drugs in the past 3 months. If a participant answered "yes" to any question, he or she received 2 or 3 follow-up items specific to that substance class.
For TAPS-1, any response other than "never" constituted a positive result; participants with positive TAPS-1 results completed the corresponding items on TAPS-2, and their responses were summed within each substance class to generate a substance-specific risk score. The scores have a potential range of 0 to 3 for tobacco and other drugs and 0 to 4 for alcohol. In clinical practice, TAPS-2 would be administered only to participants with a positive result on TAPS-1; however, for the purposes of the study, participants completed all of TAPS-2 regardless of TAPS-1 responses.
Reference Measures
The CIDI was used as the gold standard reference measure. Prior versions of the CIDI have been used widely in epidemiologic and clinical research to assess substance use disorder (SUD) based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-4) (37-41). As in our previous research (42), we used the existing CIDI items that mapped onto the DSM-5 SUD classifications (by omitting the item on legal problems and including the one on craving).
Problem use was defined as past-year use with endorsement of 1 or more items on the CIDI. This approach was taken in previous screening tool studies to identify clinically important substance use that may not be severe enough to meet the criteria for an SUD (42, 43) . The definition of an SUD was based on the standard diagnostic threshold of meeting 2 or more DSM criteria on the CIDI. In the past 12 months, how often have you used any prescription medications just for the feeling, more than prescribed, or that were not prescribed for you?
Oral Fluid Testing
The Intercept immunoassay (OraSure Technologies) objectively measured point prevalence for the following drug classes: marijuana, cocaine, phencyclidine, opiates, amphetamines, benzodiazepines, and barbiturates. It has a window of detection of up to 3 days for most drugs (44 -46) . To assist in interpretation of results, participants were assessed for medical use of medications that would be detected by the test. Oral fluid test results were not shared with participants; they were linked to the self-reported data by the participant's unique identifier.
Statistical Analysis
Concurrent validity of the interviewer-and selfadministered versions of the TAPS tool, compared with the reference standard CIDI, was assessed for the risk categories of problem use and SUD for each substance class. We calculated sensitivity, specificity, and positive and negative diagnostic likelihood ratios (LRs) (47) , with exact 95% CIs. Five participants did not complete the entire CIDI, and 1 participant did not complete the entire interviewer-administered TAPS tool. If the score for the CIDI or TAPS tool was missing for a given substance, that case was excluded from the analyses. To identify problem use, we selected cutoffs that maximized sensitivity; for SUD, the cutoffs selected were both higher than that for problem use and had the greatest sensitivity.
To assess for differences based on the sequence of TAPS tool administration, we used a generalized estimating equation to examine responses for any variation related to the order in which the 2 formats (self-vs. interviewer administered) were given (48, 49) . A 2-way crossed model was fit, and to account for the crossover nature of the data, an unstructured working correlation matrix was used under the generalized estimating equation framework. The most important parameter of interest was the interaction between order and instrument. This variable was highly significant for alcohol only, suggesting that participants' responses to selfand interviewer-administered TAPS tool questions differed based on order of administration. Alcohol use was reported by more participants who had the selfadministered tool first (38.6%) than by those who had it second (30.7%). For substances other than alcohol, diagnostic accuracy was analyzed without regard to order of administration. For alcohol, analyses also were done separately, restricted to the first version received (Appendix Tables 1 and 2 , available at www.annals .org). All analyses were conducted in SAS version 9.3 or 9.4 (SAS Institute).
Role of the Funding Source
The study was supported by a NIDA Center for Clinical Trials Network (CCTN) Cooperative Agreement. Coauthors include NIDA CCTN staff (G.S. and C.C.), who contributed to protocol development, including study design, methods, and conduct, and to manuscript preparation.
RESULTS
Participants
A total of 12 473 patients were assessed for eligibility, 48% of whom met the criteria for participation ( Figure 2) . Among those eligible, 35% agreed to participate and were randomly assigned to study groups. Of the 2000 participants who completed the measures, 1802 (90%) subsequently agreed to oral fluid testing.
As shown in Table 1 , the mean age of the participants was 46.0 years (SD, 14.7) and more than half (56.2%) were women. The prevalence of past-year use, as reported on the modified CIDI, is shown in Table 2 . Site-specific prevalence is shown in Appendix Table 3 (available at www.annals.org). Among the participants who provided a sample for oral fluid testing, point prevalence was 11.3% for illicit substances and 5.0% for nonmedical use of prescription medications.
Acceptability of the TAPS Tool
Ninety-nine percent of participants said they felt comfortable answering the TAPS tool questions, and 95% reported that they would be comfortable sharing the results with their physician. Participants differed in their preferences for interviewer-versus selfadministered screening: 31% preferred the interview, 24% preferred the self-administered version, and 45% had no preference.
Comparison of Interviewer-and SelfAdministered Versions
Overall, the interviewer-and self-administered versions of the tool performed similarly and generated the same cutoffs for problem use and SUD. Because of the similarity, only the interviewer-administered version is presented in Table 3 ; data for the self-administered version are in Appendix Table 4 (available at www. annals.org). Although small differences in sensitivity were observed, they did not follow a consistent pattern. For both versions, specificity was almost uniformly high across substance classes.
Identification of Problem Use
The optimal cutoff score for problem use was 1+. At this cutoff, the interviewer-administered tool had good sensitivity and specificity for identifying any problem use of tobacco (0.93 and 0.87, respectively) and alcohol (0.74 and 0.79, respectively). For illicit drugs, sensitivity ranged from 0.82 (marijuana) to 0.68 (cocaine). For nonmedical use of prescription drugs, sensitivity was 0.71 for opioids and 0.63 for sedatives. The 95% CIs were broad for substances with a lower prevalence in the study population. Specificity for identifying problem use was high (0.93 or greater) for all illicit and prescription drug classes. Positive LRs ranged from 3.5 for alcohol to greater than 250 for heroin, whereas negative LRs ranged from 0.08 for tobacco to 0.37 for sedatives.
Identification of SUD
The optimal cutoff score on the TAPS tool for identifying SUD was 2+. A lower cutoff of 1+ had higher sensitivity for identifying SUD, but because this was the Performance of the TAPS Tool for Substance Use Screening ORIGINAL RESEARCH optimal cutoff for problem use, it was not selected. Conversely, a higher cutoff of 3+ demonstrated high specificity for identifying SUD, but it was not selected because of unacceptably low sensitivity (less than 0.50) (Appendix Tables 5 and 6 , available at www.annals .org). At a score of 2+, sensitivity was lower for identification of SUD than for problem use (although it was 0.70 or greater for tobacco, alcohol, and marijuana) and specificity was no lower than 0.85. Positive LRs ranged from 4.7 to greater than 425, and negative LRs ranged from 0.30 to 0.52. The small number of participants with prescription stimulant use (7 with problem use and 4 with SUD identified on the CIDI) prevented us from making meaningful estimates for this substance class.
DISCUSSION
This multisite study of a substance use screening instrument found that for substances most commonly used by primary care patients (namely, tobacco, alcohol, and marijuana), the TAPS tool has good sensitivity and specificity for identifying problem use. For substances encountered less frequently in primary care, sensitivity and specificity estimates were lower and less precise, and sensitivity for detecting SUD was unacceptably low. Thus, although the TAPS tool cutoffs of 1+ for problem use and 2+ for SUD may be applied to alcohol, tobacco, and marijuana, for other drugs, any patient with a score of 1+ should be assessed further for an SUD. * Among the completer population, 5 participants did not complete the entire CIDI, 1 participant did not complete the entire intervieweradministered TAPS tool, and 1 participant did not complete the entire self-administered TAPS tool. Therefore, when the score for CIDI or TAPS was missing for a given substance, these cases were excluded from the analyses for that substance. CIDI = Composite International Diagnostic Interview; TAPS = Tobacco, Alcohol, Prescription medication, and other Substance use.
ORIGINAL RESEARCH Performance of the TAPS Tool for Substance Use Screening
Compared with other substance use screening instruments, the TAPS tool has several characteristics that make it attractive for primary care. First, it screens for and assesses use of tobacco, alcohol, and all major drug classes in a single instrument. It has the potential to be integrated easily into regular clinical workflows, which in most settings already have been designed to screen for tobacco use (required under Meaningful Use Stage 2 [50]). Second, the TAPS tool gives substancespecific risk information, which is essential for ensuring patient safety, providing feedback and education, and guiding treatment decisions. Neither the widely used Drug Abuse Screening Test (25, 51) nor the newer Screen of Drug Use (29) provides this level of detail. Third, the TAPS tool provides the option of patient selfadministration, which may facilitate more accurate reporting of stigmatized behavior (52, 53) , ensure fidelity of administration (54, 55) , increase patient comfort (56) , and reduce the burden on staff. It has the potential to be completed through a Web-based patient portal or on a kiosk or tablet computer in the clinic, from which screening results can be uploaded to the electronic health record.
In some practice settings, a role still may exist for very brief screens-such as the Substance Use Brief Screen (27) or single-item screening questions for alcohol and drugs (24 -26)-to quickly identify patients with any unhealthy substance use. The 4-item TAPS-1 has the potential to accomplish this task, and future reports will examine its performance as a stand-alone instrument. Yet, for the significant proportion of patients who have a positive result on a brief screening instrument (28% to 29% in some studies [26, 27] ), an efficient follow-up assessment is essential for risk stratification and to guide care. For alcohol use, this may be accomplished with the AUDIT (Alcohol Use Disorders Identification Test) or AUDIT-C (Alcohol Use Disorders Identification Test Consumption Questions), both of which have been adopted widely (36, 43, 57, 58) . No similarly brief, structured assessment tool has existed to screen for use of other drugs. Until now, the World Health Organization's ASSIST was the only screening tool providing substance-specific risk stratification for drugs; however, the length and complexity of the ASSIST have hindered its implementation in primary care settings (32, 59) (although a computer self-administered version might be more feasible [60] ). The TAPS tool streamlines the ASSIST so that this assessment may be performed relatively quickly. Future research may explore whether TAPS-2 can be simplified further by reducing either the number of substances queried or the number of items. * Values are numbers (percentages) unless otherwise indicated. † American Indian or Alaska Native (n = 12), unknown (n = 32), and other/not specified (n = 69). ‡ Refers to "keeping house" (n = 66) and other/not specified (n = 41). The TAPS tool has some shortcomings. Sensitivity was low for detecting problem use of some substances. It is possible that this lack of sensitivity reflects differences between the time frame of our reference standard measure and the TAPS tool. Although the TAPS tool screens for use in the past 12 months (TAPS-1), the final score is based on use in the past 3 months (TAPS-2). As a result, the TAPS tool may fail to identify individuals whose problem use in the past year did not continue into the most recent 3-month period. However, by focusing on current use, the TAPS tool identifies patients who are most in need of clinical intervention, which is important in primary care settings, where providers have multiple demands on their time. We have limited ability to draw comparisons with other instruments that screen for illicit and prescription drug use, because only the ASSIST (and its shortened version, ASSIST-Lite) provides substance-specific results. Validation studies of the ASSIST have not reported its diagnostic accuracy at the cutoffs recommended by the World Health Organization, and were conducted in samples that included drug treatment and psychiatric patients (28, 61, 62) . The ASSIST-Lite (on which TAPS-2 is based) was developed from secondary analysis of data from the validation study of the full ASSIST (32), and its performance was not assessed previously.
Performance of the TAPS tool in detecting problem use and SUD was poorest for prescription medications, particularly with the self-administered version, but it still compares favorably with an existing brief screening tool that specifically queries nonmedical use of prescription drugs (27) . The relatively low sensitivity of screening for this substance class might be the result of confusion among participants regarding what constitutes nonmedical use (63), poor comprehension, or question fatigue due to the length and complexity of these items on TAPS-1. The difference in how nonmedical use is described in TAPS-1 versus TAPS-2 may have confused some respondents. In practice, performance of the TAPS tool and similar screening tools may be compromised further by patients' reluctance to disclose misuse of a medication to the physician who has prescribed it.
Interviewer-administered screening approaches may be challenging to implement in practice because they require staff time and training, and interviewers can modify the screening language in ways that compromise the tool's accuracy (54, 55) . Self-administered tools might help to promote disclosure of substance use (52, 53, 64 -66) , but this format may not be feasible in all practice settings. Self-administration on an iPad may be problematic for patients with low literacy or poor vision, although audio guidance might help to overcome these barriers. Elderly patients may have difficulty using an iPad. Tablet computers currently are uncommon in primary care settings, and their use would require considerations of workflow, security, and hygiene. 
Our study design has several limitations. Although our sample was large, for most drug classes we did not have enough participants with problem use or SUD to develop and then test the cutoffs in separate samples. The low prevalence of certain drugs also led to poor precision in some estimates, particularly with respect to identifying an SUD. The RAs administering the CIDI were not blinded to participant responses on the interviewer-administered TAPS tool, which may have biased the CIDI responses. Our analyses relied on selfreported substance use, which has consistently shown good accuracy in research studies (67-70), but nonetheless depends on accurate and truthful disclosure of use. Data were collected with an assurance of confidentiality and anonymity, as they were for all previous studies examining the concurrent validity of substance use screening tools, to increase the accuracy of selfreporting. In clinical practice, where patients are aware that medical providers will view their screening results, the diagnostic accuracy of the TAPS tool may differ (54, 56, 68, 71) .
The TAPS tool was developed and evaluated only in English, which may limit its application in some settings. Although we recruited from clinics with geographic and demographic diversity, our participants may not be representative of patients seen in all primary care settings. In particular, we had a high proportion of African Americans and individuals with lower levels of education in our sample. Many eligible patients declined to participate in the study, and we cannot assess how their inclusion would have affected the tool's performance.
Our study also has notable strengths, including enrollment of a large and diverse sample of adult primary care patients, high rates of completion of the reference standard measures, and a rigorous approach to testing both a self-and interviewer-administered version of the TAPS tool.
Having information about a patient's substance use is essential for ensuring the quality and safety of medical care. This study supports the use of the TAPS tool (at a cutoff of 1+) in screening primary care patients for problem substance use. The tool also may detect alcohol, tobacco, and marijuana use disorders, although further refinement is needed before it can be broadly recommended as a screener for SUD. Because it asks a limited number of questions to identify problem use of all commonly used substances and has the flexibility to be either self-administered or completed as an interview, the TAPS tool has the potential to ease barriers to incorporating substance use screening into busy clinical environments. 
